Literature DB >> 9559206

Utility of serology in determining Helicobacter pylori eradication after therapy.

C A Fallone1, V G Loo, A N Barkun.   

Abstract

OBJECTIVE: To determine the usefulness of four serological tests in confirming cure of H pylori infection before the previously reported six-month post-treatment delay. PATIENTS AND METHODS: As part of a prospective, blinded, controlled trial, in which patients with duodenal ulcers were randomized to receive different combinations of antibiotics, serum samples were obtained in 89 patients before treatment, as well as on several occasions after treatment. Antibody titres were determined by ELISA with Bio-Rad immunoglobulin (Ig) A, Bio-Rad IgG, Pyloriset EIA-A for IgA and Pyloriset EIA-G for IgG. Eradication was confirmed with antral biopsy three months after therapy.
RESULTS: The percentage drop in titre following treatment was significantly larger for the group of patients who were treated successfully with all four kits. Optimal cut-offs for identifying successful therapy were determined, and accuracy improved as the interval between testing and therapy was prolonged. Six months after therapy, the IgG test from Bio-Rad achieved 100% sensitivity and 80% specificity, and that from Pyloriset achieved 88% sensitivity and 100% specificity. At three months, however, test performance was quite good, with 90% sensitivity and 80% specificity when using a Pyloriset IgA titre drop of 20% or greater to predict successful eradication.
CONCLUSION: Serology is a simple, easily available, noninvasive method that exhibits good positive predictive value in the confirmation of successful cure of H pylori infection three or six months after treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559206     DOI: 10.1155/1998/303628

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  4 in total

1.  An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

Authors:  S J Veldhuyzen van Zanten; N Flook; N Chiba; D Armstrong; A Barkun; M Bradette; A Thomson; F Bursey; P Blackshaw; D Frail; P Sinclair
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

2.  Dynamics of Helicobacter pylori-specific immunoglobulin G for 2 years after successful eradication of Helicobacter pylori infection in an American Indian and Alaska Native population.

Authors:  Karen M Miernyk; Dana L Bruden; Michael G Bruce; Brian J McMahon; Thomas W Hennessy; Helen V Peters; Debby A Hurlburt; Frank Sacco; Alan J Parkinson
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

3.  Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.

Authors:  Seung Won Ra; Marc A Sze; Eun Chong Lee; Sheena Tam; Yeni Oh; Nick Fishbane; Gerard J Criner; Prescott G Woodruff; Stephen C Lazarus; Richard Albert; John E Connett; Meilan K Han; Fernando J Martinez; Shawn D Aaron; Robert M Reed; S F Paul Man; Don D Sin
Journal:  Respir Res       Date:  2017-05-30

Review 4.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.